1. bookVolume 25 (2017): Issue 2 (April 2017)
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

Therapy-related myelodysplastic syndrome after successful treatment of acute promyelocytic leukemia: case report and literature review

Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Abstract

In the 2016 revision of the World Health Organization classification the term therapy-related myeloid neoplasia (t-MN) defines a subgroup of acute myeloid leukemia (AML) comprising patients who develop myelodysplastic syndrome (MDS-t) or acute myeloid leukemia (AML-t) after treatment with cytotoxic and/or radiation therapy for various malignancies or autoimmune disorders. We report the case of a 36 year old patient with t-MN (t-MDS) after achieving complete remission (CR) of a PML-RARA positive acute promyelocytic leukemia (APL) at 32 months after diagnosis. Initially classified as low risk APL and treated according to the AIDA protocol - induction and 3 consolidation cycles - the patient achieved a complete molecular response in September 2013 and started maintenance therapy. On follow-up PML-RARA transcript remained negative. In January 2016 leukopenia and thrombocytopenia developed and a peripheral blood smear revealed hypogranular and agranular neutrophils. Immunophenotyping in the bone marrow aspirate identified undifferentiated blast cells that did not express cytoplasmic myeloperoxidase. The cytogenetic study showed normal karyotype. The molecular biology tests not identified PMLRARA transcript. A diagnosis of t-MDS (AREB-2 - WHO 2008) was established. Treatment of AML was started with 2 “3+7” regimens and 1 MEC cycle. Two months from diagnosis, while in CR, an allogeneic HSCT from an unrelated HLA compatible donor was performed after myeloablative regimen. An unfavorable clinical evolution was followed by death on day 9 after transplantation. The occurrence of t-MNs during CR of APL represents a particular problem in terms of follow-up and differential diagnosis of relapse and constitutes a dramatic complication for a disease with a favorable prognosis.

This work was supported by the grants PN 41-087 /PN2-099 from the Romanian Ministry of Research and Technology

Keywords

1. Vardiman JW, Arber DA, Brunning RD, Larson RA, Matutes E, Baumann I, et al. Therapy - related myeloid neoplasms in: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth Ed. Lyon France: IARC Press 2008: 127-129.Search in Google Scholar

2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Michelle M, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391-2405. DOI: 10.1182/blood-2016-03-64354410.1182/blood-2016-03-64354427069254Search in Google Scholar

3. Larson RA. Therapy - related myeloid neoplasms. Haematologica 2009 April;94(4):454-9. DOI: 10.3324/ haematol.2008.00515710.3324/haematol.2008.005157266360719336749Search in Google Scholar

4. Heuser M. Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment? Hematology Am Soc Hematol Educ Program. 2016 Dec;(1):24-32. DOI: 10.1182/asheducation-2016.1.2410.1182/asheducation-2016.1.24614251427913458Search in Google Scholar

5. Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, Churpek MM, et al. Inherited mutations in cancer succeptibility genes are common among survivors of breast cancer who develop therapy - related leukemia. Cancer. 2016 Jan;122(2):304-11. DOI: 10.1002/ cncr.2961510.1002/cncr.29615470798126641009Search in Google Scholar

6. Kayser S, Dohner K, Krauter J, Köhne CH, Horst HA, Held G, et al. The impact of therapy - related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011 Feb; 117(7):2137-45. DOI: 10.1182/blood-2010-08-30171310.1182/blood-2010-08-30171321127174Search in Google Scholar

7. Montesinos P, Gonzalez JD, Gonzalez J, Rayo’n C, de Lisa E, Amigo ML, et al. Therapy - Related Myeloid Neoplasms in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline based chemotherapy. J Clin Oncol. 2010 Aug;28(24):3872-9. DOI: 10.1200/JCO.2010.29.226810.1200/JCO.2010.29.226820625122Search in Google Scholar

8. Lo-Coco F, Cicconi L, Breccia M. Current standard treatment of acute promyelocytic leukemia. British Journal of Haematology. 2016 Mar;172(6):841-4. DOI: 10.1111/bjh.1389010.1111/bjh.1389026687281Search in Google Scholar

9. Zeidan AM, Gore SD. New strategies in acute promyelocytic leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management Approach. Clinical Cancer Research. 2014 Oct; 20(19):4985-93. DOI: 10.1158/1078-0432.CCR-13-272510.1158/1078-0432.CCR-13-2725488275825274377Search in Google Scholar

10. Tomita A, Kiyoi H, NaoeT. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. Int J Hematol. 2013 Jun;97(6):717-25. DOI: 10.1007/ s12185-013-1354-410.1007/s12185-013-1354-423670176Search in Google Scholar

11. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008 March; 111(5):2505-14. DOI: 10.1182/blood-2007-07-10279810.1182/blood-2007-07-10279818299451Search in Google Scholar

12. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayón C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000 Aug; 96:1247-53.Search in Google Scholar

13. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommandations from an expert panel on behalf of the European Leukemia Net. Blood 2009 Feb;113(9):1875-91. DOI: 10.1182/ blood-2008-04-15025010.1182/blood-2008-04-150250Search in Google Scholar

14. Sanz MA, Lo-Coco F. Modern Approaches to Treating Acute Promyelocytic Leukemia. J Clin Oncol. 2011 Feb;29(5):495-503. DOI: 10.1200/JCO.2010.32.106710.1200/JCO.2010.32.1067Search in Google Scholar

15. Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010 Oct; 116(17):3171-9. DOI: 10.1182/ blood-2010-03-27619610.1182/blood-2010-03-276196Search in Google Scholar

16. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. N Engl J Med 2013 Jul;369(2):111-21. DOI: 10.1056/ NEJMoa130087410.1056/NEJMoa1300874Search in Google Scholar

17. Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, et al. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol 2016 Jul;1-14.Search in Google Scholar

18. Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet Oncology 2015 Oct;16(13): 1295-305. DOI: 10.1016/S1470-2045(15)00193-X10.1016/S1470-2045(15)00193-XSearch in Google Scholar

19. Imagawa J, Harada Y, Shimomura T, Tanaka H, Okikawa Y, Hyodo H, et al. Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia. Blood 2010 Dec; 116(26):6018-22. DOI: 10.1182/ blood-2010-06-28938910.1182/blood-2010-06-289389Search in Google Scholar

20. Eghtedar A, Rodriquez I, Kantarjian H, O’Brien S, Daver N, Manero GG, et al. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid pluss arsenic trioxide. Leuk. Lymphoma 2015 May;56(5):1342-5. DOI: 10.3109/10428194.2014.95314310.3109/10428194.2014.953143Search in Google Scholar

21. Latagliata R, Petti MC, Fenu S, Mancini M, Spiriti MAE, Breccia M, et al. Therapy-related myelodysplastic syndrome- acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002 Feb; 99(3):822-4. DOI: 10.1182/blood.V99.3.82210.1182/blood.V99.3.822Search in Google Scholar

22. Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, et al. Risk-adapted treatment of acute promyelocytic leukemia based on alltrans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood.2010 Jun;115(25):5137-46. DOI: 10.1182/ blood-2010-01-26600710.1182/blood-2010-01-266007Search in Google Scholar

23. Panizo C, Patino A, Lecumberri R, Calasanz MJ, Odero MD, Bendandi M, et al. Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: clinical and genetic features of two cases. Cancer Genetics and Cytogenetics 2003 Jul; 143(2):178-81. DOI: 10.1016/S0165-4608(02)00859-210.1016/S0165-4608(02)00859-2Search in Google Scholar

24. Lobe I, Rigal-Huguet F, Vekhoff A, Desablens B, Bordessoule D, Mounier C, et al. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia. 2003 Aug;17(8):1600-4. DOI: 10.1038/sj.leu.240303410.1038/sj.leu.240303412886249Search in Google Scholar

25. Coliţă A, Nicoară S, Butoianu E, Munteanu N, Ursea C, Poppa C, et al. Acute promyelocytic leukemia. A study of 119 cases and a review of the literature. Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna. 1988 Jan-Feb;40(1):21-32.Search in Google Scholar

26. Colita A, Vasilache D, Gheorghe A, Jardan C, Jardan D, Dragomir M, et al. Acute promyelocytic leukemia: the importance of the laboratory examination for the diagnosis and the dynamic following of the answer to the treatment. Romanian Review of the Laboratory Medicine 2013 Jun; 21(2/4):S60.Search in Google Scholar

27. Coombs CC, Tavakkoli M, Tallman MS: Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer Journal 2015 Feb;5, e304. DOI: 10.1038/bcj.2015.2510.1038/bcj.2015.25445032525885425Search in Google Scholar

28. Schmiegelow K, Al - Modhwahii, Andersen MK, Behrendtz M, Forestier E, Hasle H, et al. Methotrexate (6- mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia. Results from the NOPHO ALL- 92 study. Blood 2009;113:6077-884. DOI: 10.1182/blood-2008-11-18788010.1182/blood-2008-11-187880269923019224761Search in Google Scholar

29. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017 Jan;129(4):424-47. DOI: 10.1182/blood-2016-08-73319610.1182/blood-2016-08-733196529196527895058Search in Google Scholar

30. Watts JM, Tallman MS. Acute promyelocytic leukemia: What is the new standard of care? Blood Rev 2014 Sep; 28(5):205-12. DOI: 10.1016/j.blre.2014.07.00110.1016/j.blre.2014.07.00125107311Search in Google Scholar

31. Esteve J, Escoda L, Martín G, Rubio V, Díaz- Mediavilla J, González M, et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracyclinebased chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia 2007 Mar;21(3):446-52. DOI: 10.1038/sj.leu.2404501 10.1038/sj.leu.240450117205057Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo